What is the best oral contraceptive pill for treating acne in an adolescent girl?

Best Oral Contraceptive for Acne in Adolescent Girls

Any of the four FDA-approved combined oral contraceptives (COCs) are appropriate first-line choices for treating acne in adolescent girls who desire contraception: norgestimate/ethinyl estradiol, norethindrone acetate/ethinyl estradiol, drospirenone/ethinyl estradiol, or drospirenone/ethinyl estradiol/levomefolate—all demonstrate similar efficacy, and selection should prioritize safety profile, with norgestimate/ethinyl estradiol being preferred due to lower VTE risk compared to drospirenone-containing formulations. 1

The Evidence-Based Approach

The 2024 American Academy of Dermatology guidelines provide clear direction: all four FDA-approved COC formulations for acne work through the same anti-androgenic mechanism—they decrease ovarian androgen production, increase sex hormone-binding globulin, reduce free testosterone, and block androgen receptors. 1 When pooled data from 10 randomized controlled trials were analyzed, COCs showed a 45% greater likelihood of achieving clear or almost clear skin compared to placebo, with significant reductions in both inflammatory (15.81% greater reduction) and non-inflammatory lesions. 1

Why All Four FDA-Approved Options Work Similarly

The key insight is that when combined with estrogen, all progestins yield net anti-androgenic properties—even those derived from testosterone. 1 This means:

• Third-generation progestins (norgestimate, desogestrel) are less androgenic than earlier generations
• Fourth-generation progestins (drospirenone) have inherent anti-androgenic properties as a spironolactone analogue
• First-generation progestins (norethindrone acetate) still provide anti-androgenic effects when combined with ethinyl estradiol

Research confirms this equivalence: drospirenone/ethinyl estradiol 20 mcg showed 46.3% reduction in total lesions versus 30.6% for placebo 2, while dienogest/ethinyl estradiol demonstrated 65.6% reduction in inflammatory lesions versus 49.4% for placebo 3—clinically similar outcomes across different progestin types.

The Safety-Based Decision Algorithm

For adolescents specifically, prioritize norgestimate/ethinyl estradiol or norethindrone acetate/ethinyl estradiol because:

1. VTE risk matters: Drospirenone-containing COCs carry an estimated VTE incidence of 10 per 10,000 person-years versus 3-9 for other COCs 1
2. While this absolute risk remains low in adolescents (who lack additional risk factors like age >35, smoking, hypertension), why accept higher risk when efficacy is equivalent?
3. All formulations are available as generics, so cost is not a differentiating factor 1

Critical Pitfalls to Avoid

Never prescribe progestin-only contraceptives for acne—pills, injections, IUDs, or implants may actually worsen acne due to unopposed androgenic effects. 1 This is a common error that can undermine treatment.

Before prescribing any COC to an adolescent:

• Obtain comprehensive medical history focusing on VTE risk factors, migraines with aura, hypertension, diabetes, smoking status
• Measure blood pressure
• Rule out pregnancy (history-based criteria or urine test) 1
• Screen for contraindications to estrogen

Practical Prescribing

Expect to see improvement by cycle 6 (6 months), which is when clinical trial endpoints were measured. 1, 2, 4 The adolescent needs to understand this is not a rapid-acting acne treatment but provides sustained benefit with continued use.

Recent evidence suggests norgestimate specifically meets both low VTE risk and anti-androgenic efficacy requirements, making it an optimal first choice. 5 However, if the patient or family has concerns about any specific formulation, switching between the four FDA-approved options is reasonable given their similar efficacy profiles.